432 related articles for article (PubMed ID: 15518912)
61. Paradoxical antagonism of PACAP receptor signaling by VIP in Xenopus oocytes via the type-C natriuretic peptide receptor.
Lelièvre V; Hu Z; Ioffe Y; Byun JY; Flores A; Seksenyan A; Waschek JA
Cell Signal; 2006 Nov; 18(11):2013-21. PubMed ID: 16723209
[TBL] [Abstract][Full Text] [Related]
62. Chemical synthesis and formulation design of a PEGylated vasoactive intestinal peptide derivative with improved metabolic stability.
Onoue S; Matsui T; Kato M; Mizumoto T; Liu B; Liu L; Karaki S; Kuwahara A; Yamada S
Eur J Pharm Sci; 2013 Jun; 49(3):382-9. PubMed ID: 23608612
[TBL] [Abstract][Full Text] [Related]
63. Role of c-fos gene in vasoactive intestinal peptide promoted synthesis of pulmonary surfactant phospholipids.
Li L; She H; Yue SJ; Qin XQ; Guan CX; Liu HJ; Luo ZQ
Regul Pept; 2007 May; 140(3):117-24. PubMed ID: 17218027
[TBL] [Abstract][Full Text] [Related]
64. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
Delgado M; Ganea D
J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043
[TBL] [Abstract][Full Text] [Related]
65. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity.
Ganea D; Rodriguez R; Delgado M
Cell Mol Biol (Noisy-le-grand); 2003 Mar; 49(2):127-42. PubMed ID: 12887096
[TBL] [Abstract][Full Text] [Related]
66. PACAP and VIP promote initiation of electrophysiological activity in differentiating embryonic stem cells.
Chafai M; Louiset E; Basille M; Cazillis M; Vaudry D; Rostène W; Gressens P; Vaudry H; Gonzalez BJ
Ann N Y Acad Sci; 2006 Jul; 1070():185-9. PubMed ID: 16888163
[TBL] [Abstract][Full Text] [Related]
67. Mechanisms of VIP-induced neuroprotection against neonatal excitotoxicity.
Rangon CM; Dicou E; Goursaud S; Mounien L; Jégou S; Janet T; Muller JM; Lelièvre V; Gressens P
Ann N Y Acad Sci; 2006 Jul; 1070():512-7. PubMed ID: 16888217
[TBL] [Abstract][Full Text] [Related]
68. Physicochemical and pharmacological characterization of novel vasoactive intestinal peptide derivatives with improved stability.
Onoue S; Misaka S; Ohmori Y; Sato H; Mizumoto T; Hirose M; Iwasa S; Yajima T; Yamada S
Eur J Pharm Biopharm; 2009 Sep; 73(1):95-101. PubMed ID: 19481602
[TBL] [Abstract][Full Text] [Related]
69. Expression of VIP and/or PACAP receptor mRNA in peptide synthesizing cells within the suprachiasmatic nucleus of the rat and in its efferent target sites.
Kalamatianos T; Kalló I; Piggins HD; Coen CW
J Comp Neurol; 2004 Jul; 475(1):19-35. PubMed ID: 15176082
[TBL] [Abstract][Full Text] [Related]
70. Pituitary adenylate cyclase-activating polypeptide inhibits caspase-3 activity but does not protect cerebellar granule neurons against beta-amyloid (25-35)-induced apoptosis.
Vaudry D; Cottet-Rousselle C; Basille M; Falluel-Morel A; Fournier A; Vaudry H; Gonzalez BJ
Regul Pept; 2004 Dec; 123(1-3):43-9. PubMed ID: 15518892
[TBL] [Abstract][Full Text] [Related]
71. Bone morphogenetic protein down-regulation of neuronal pituitary adenylate cyclase-activating polypeptide and reciprocal effects on vasoactive intestinal peptide expression.
Pavelock KA; Girard BM; Schutz KC; Braas KM; May V
J Neurochem; 2007 Feb; 100(3):603-16. PubMed ID: 17181550
[TBL] [Abstract][Full Text] [Related]
72. Expression of vasoactive intestinal peptide and related receptors in overcirculation-induced pulmonary hypertension in piglets.
Vuckovic A; Rondelet B; Brion JP; Naeije R
Pediatr Res; 2009 Oct; 66(4):395-9. PubMed ID: 19581838
[TBL] [Abstract][Full Text] [Related]
73. Development of dry powder inhalation system of novel vasoactive intestinal peptide (VIP) analogue for pulmonary administration.
Ohmori Y; Onoue S; Endo K; Matsumoto A; Uchida S; Yamada S
Life Sci; 2006 Jun; 79(2):138-43. PubMed ID: 16458931
[TBL] [Abstract][Full Text] [Related]
74. Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide.
Yung SL; Dela Cruz F; Hamren S; Zhu J; Tsutsumi M; Bloom JW; Caudle M; Roczniak S; Todd T; Lemoine L; MacDougall M; Shanafelt AB; Pan CQ
J Biol Chem; 2003 Mar; 278(12):10273-81. PubMed ID: 12525492
[TBL] [Abstract][Full Text] [Related]
75. Role of VIP and PACAP in islet function.
Winzell MS; Ahrén B
Peptides; 2007 Sep; 28(9):1805-13. PubMed ID: 17559974
[TBL] [Abstract][Full Text] [Related]
76. VIP and PACAP stimulate TSH release from the bullfrog pituitary.
Okada R; Yamamoto K; Ito Y; Mochida H; Tonon MC; Fournier A; Leprince J; Vaudry H; Kikuyama S
Peptides; 2007 Sep; 28(9):1784-9. PubMed ID: 17482721
[TBL] [Abstract][Full Text] [Related]
77. Inhibitory effects of pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) on food intake in the goldfish, Carassius auratus.
Matsuda K; Maruyama K; Nakamachi T; Miura T; Uchiyama M; Shioda S
Peptides; 2005 Sep; 26(9):1611-6. PubMed ID: 16112400
[TBL] [Abstract][Full Text] [Related]
78. PACAP, VIP, and PHI: effects on AC-, PLC-, and PLD-driven signaling systems in the primary glial cell cultures.
Dejda A; Jozwiak-Bebenista M; Nowak JZ
Ann N Y Acad Sci; 2006 Jul; 1070():220-5. PubMed ID: 16888170
[TBL] [Abstract][Full Text] [Related]
79. Neuritogenesis induced by vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide, and peptide histidine methionine in SH-SY5y cells is associated with regulated expression of cytoskeleton mRNAs and proteins.
Héraud C; Hilairet S; Muller JM; Leterrier JF; Chadéneau C
J Neurosci Res; 2004 Feb; 75(3):320-9. PubMed ID: 14743445
[TBL] [Abstract][Full Text] [Related]
80. Opposing effects by pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide on hippocampal synaptic transmission.
Ciranna L; Cavallaro S
Exp Neurol; 2003 Dec; 184(2):778-84. PubMed ID: 14769370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
